Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjögren's syndrome

Annals of the Rheumatic Diseases

Volumn 72, Issue 12, 2013, Pages 2048-2050

  Pollard, R P E ^a   Abdulahad, W H ^a   Bootsma, H ^a   Meiners, P M ^a   Spijkervet, F K L ^a   Huitema, M G ^a   Burgerhof, J G M ^a   Vissink, A ^a   Kroese, F G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CXCL9 CHEMOKINE; CYTOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RANTES; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMORAL IMMUNE DEFICIENCY; LETTER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SJOEGREN SYNDROME; TREATMENT OUTCOME;

B CELLS; CHEMOKINES; CYTOKINES; SJÖGREN'S SYNDROME; TREATMENT;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CYTOKINES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; LYMPHOCYTE DEPLETION; MALE; SJOGREN'S SYNDROME;

EID: 84887421852     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203447     Document Type: Letter

References (12)

1. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome. Oral Dis 2009;15:519-26.
2. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
3. Pollard RP, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis 2013;72:146-8.
4. Reksten TR, Jonsson MV, Szyszko EA, et al. Cytokine and autoantibody profiling related to histopathological features in primary Sjögren's syndrome. Rheumatology 2009;48:1102-6.
5. Abdulahad WH, Meijer JM, Kroese F G M, et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome a double-blind, placebo-controlled study. Arthritis Rheum 2011;63:1116-23.
6. Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95.
7. Thacker SG, Berthier CC, Mattinzoli D, et al. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010;185:4457-69.
8. Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006;3:e491.
9. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-82.
10. Lund FE, Garvy BA, Randall TD, et al. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005;8:25-54.
11. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012;209:1001-10.
12. Kallenberg CG, Vissink A, Kroese FG, et al. What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis? Arthritis Res Ther 2011;13:205.